Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPB-01 Maintenance Therapy for CIDP
NCT01824251Phase 3Completed
- Sponsor
- Nihon Pharmaceutical
- Start
- Apr 2013
- Primary completion
- Sep 2015
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of NPB-01-ME in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Nihon Pharmaceutical. Primary endpoints: Proportion of patients with more than 1 point improvement in the INCAT score relative to baseline at 28 weeks and Proportion of patients with more than 1 point exacerbation in the INCAT score relative to 28 weeks. Started Apr 2013; status: completed.
02
Drugs
NPB-01-ME
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT01824251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824251.